Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As Add On Therapy In Type 2 Diabetic Patients
Abstract
BACKGROUND: SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM). Herein, we aimed to assess the efficacy and safety profile of empagliflozin versus dapagliflozin in type 2 diabetic patients.
METHODS: In this randomized controlled trial, type 2 diabetic patients with inadequate glycaemic control HbA1c 7.5-11% with different first line anti diabetic medications were randomly divided in to two groups. Group A were given tablet Empagliflozin 25 mg while Group B were given tablet Dapagliflozin 10mg over a period of 12 weeks. The primary end point was to measures efficacy profile in terms of changes in body weight, BMI, fasting blood sugar and HbA1c. The secondary end point was to determine safety and tolerability profile.
RESULTS: After 12 weeks of treatment body weight was reduced significantly in both groups empagliflozin - 2.9±6.4 kg (p₌0.002) versus dapagliflozin -1.7±2.4 (p₌0.007). However, comparison between two groups was non-significant (p₌0.032). FBS was reduced in both study groups empagliflozin - 75.6±43.5 mg/dl versus dapagliflozin -63.5 ± 60.5 mg/dl with p<0.01. However, empagliflozin caused a significant reduction in fasting blood sugar as compared to dapagliflozin (p₌0.001). HbA1c was also significantly reduced in both groups empagliflozin -1.7±0.9% versus dapagliflozin -1.2±1.4% with p < 0.01 . However, empagliflozin caused a more significant reduction in HbA1c as…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.